In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion. The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download. And all the graphics are available as well.
Global HIV Prevention R&D Investment by Technology Category, 2000-2017
HIV Prevention R&D Trial Participants by Region in 2017
Participation of volunteers and the engagement of communities in which trials take place is essential to conducting HIV prevention research. In 2017, there were nearly 600,000 participants in HIV prevention research trials globally, mostly originating from sub-Saharan Africa, Europe, North America and Asia. A majority of participants were enrolled in research investigating TasP and PrEP, and while there are trials aimed specifically at men who have sex with men (MSM), transgender individuals and people who inject drugs, most of the studies do not specify the need to include members of key populations.
The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.
Investment in HIV Prevention R&D by Top Philanthropic Funders in 2017
Global philanthropic funding increased by 4.1 percent from 2016 levels and amounted to US$164 million, or 14.6 percent of overall funding. The Bill and Melinda Gates Foundation (BMGF) remained the largest funder and increased its contribution by 6.6 percent, to US$150.2 million. Wellcome Trust investment fell for the fifth consecutive year to an annual US$2 million.
The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.
HIV Vaccine Science, Research, Updates and Advocacy
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of PxPulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.
The Stories of HIV Vaccines in 2018—From science to stakeholder engagement
This four-pager explores stories about stakeholder engagement in the current suite of efficacy trials as well as stories around global support for vaccine research in the age of an expanded HIV prevention landscape.
Vaccines Efficacy Trials: A surge of activity
A picture of the status of vaccine trials since 2003: The four trials shown here represent an unprecedented number of late phase trials underway in vaccines research.
Prevention Research & Oral PrEP Rollout: The evolving context for HIV prevention research
Many of the current or planned prevention trials are taking place in countries where daily oral PrEP is available or will be soon. This infographic shows the status PrEP and the location of scheduled trials by country.
Vaccine and Antibody Trial Participant Recruitment, 2018
A global snapshot of total numbers of participants in trials by country.
Three Perspectives, Two Trials and One Big Goal
With more efficacy trials underway today than ever before in HIV prevention research, this episode of Px Pulse zooms in on two that have most recently launched: one of two trials testing a long-acting injectable antiretroviral called cabotegravir (HPTN 084), and the study of a “mosaic” vaccine developed by Janssen Pharmaceuticals (HVTN 705/HPX2008).
NIH-Funded HIV Trial Networks: A family tree
This graphic provides a visual history of the DAIDS Networks and a look at what’s proposed for the next funding cycle. It appears in AVAC Report 2017: Mixed messages and how to untangle them.